Allen Institute for Artificial Intelligence logo

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Glutathione and Ifosfamide



Research Papers that Mention the Interaction

The profile of GSH recovery in plasma after ifosfamide and the fact that mesna could not reduce GSH disulfides in vitro suggest that the observed GSH depletion in plasma in 60% of the patients may be related to direct reactions of GSH with ifosfamide metabolites and/or mesna.
Clinical cancer research : an official journal of the American Association for Cancer Research  •  2000  |  View Paper
Ifosfamide , a clinically potent chemotherapeutic agent, causes the depletion of intracellular glutathione ( GSH ) levels in various cell types.
Blood  •  2003  |  View Paper
The intracellular GSH level in CTL, and to a lower extent in NK cells, was reduced more substantially following an ifosfamide treatment compared with a mafosfamide treatment.
Experimental hematology  •  1997  |  View Paper
IFEX caused a 20% or greater suppression of intracellular GSH levels in nine patients, eight of whom achieved complete remission of their disease.
Ifosfamide (IFEX), an alkylating agent, has been demonstrated to decrease intracellular GSH levels in vitro in malignant cell lines and in vivo in peripheral blood lymphocytes (PBL) obtained from patients with cancer.
These data suggest that IFEX suppresses intracellular GSH levels in PBL from patients with ovarian cancer and that this suppression correlates closely with the subsequent clinical outcome.
Cancer Chemotherapy and Pharmacology  •  1997  |  View Paper
Besides, ifosfamide metabolites (in vitro) as well as ifosfamide treatment (in vivo) have been shown to decrease cellular GSH availability.
Blood cell GSH levels decreased significantly (P < 0.05) during the 3- and 10-day ifosfamide treatment schedules; the 24-h treatment had no effect.
If GSH levels in blood cells reflect those in tumors/other tissues, the present results indicate that ifosfamide may be used clinically to decrease GSH levels.
Clinical cancer research : an official journal of the American Association for Cancer Research  •  1995  |  View Paper
There is considerable evidence that the intracellular status of glutathione (GSH) plays a major role in modifying the cytotoxicity of ifosfamide in cells and tissues.
Molecular aspects of medicine  •  1993  |  View Paper
Ifosfamide can deplete intracellular glutathione levels and because doxorubicin resistance may be associated with elevated levels of intracellular glutathione these drugs were combined in an attempt to overcome clinical cytotoxic drug resistance.
Cancer  •  1990  |  View Paper
The glutathione levels in lymphocytes isolated from a patient undergoing an eight hour infusion of ifosfamide showed a marked decrease to about 30% of their original value.
Biochemical pharmacology  •  1989  |  View Paper
IFO significantly increased serum creatinine, blood urea nitrogen (BUN), urinary carnitine excretion and clearance, creatine phosphokinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), intramitochondrial acetyl-…-SH and thiobarbituric acid reactive substances (TBARS) in cardiac tissues and significantly decreased adenosine triphosphate (ATP) and total carnitine and reduced glutathione ( GSH ) content … tissues.
Oxidative medicine and cellular longevity  •  2010  |  View Paper
IFO caused a significant reduction in renal GSH , significant increases in renal MDA, and NOx, and up-regulated iNOS.
Toxicology research  •  2021  |  View Paper
Show More